Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-TARGET: Precision Medicine Trial for Relapsed/Refractory T-ALL
NCT07522801Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of venetoclax, tofacitinib oral solution, everolimus, Asparaginase erwinia chrysanthemi, azacitidine in t-cell acute lymphoblastic leukemia (T-ALL). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
venetoclaxtofacitinib oral solutioneverolimusAsparaginase erwinia chrysanthemiazacitidine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07522801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522801.